Jacobs & Co. CA Sells 50,340 Shares of Pfizer Inc. (NYSE:PFE)

Jacobs & Co. CA trimmed its stake in Pfizer Inc. (NYSE:PFE) by 17.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 238,022 shares of the biopharmaceutical company’s stock after selling 50,340 shares during the period. Jacobs & Co. CA’s holdings in Pfizer were worth $6,314,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Harbor Capital Advisors Inc. grew its stake in Pfizer by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 114,499 shares of the biopharmaceutical company’s stock worth $3,038,000 after buying an additional 2,805 shares during the last quarter. Hilltop National Bank grew its stake in Pfizer by 8.2% during the 4th quarter. Hilltop National Bank now owns 19,077 shares of the biopharmaceutical company’s stock worth $506,000 after buying an additional 1,450 shares during the last quarter. A. D. Beadell Investment Counsel Inc. grew its stake in Pfizer by 7.7% during the 4th quarter. A. D. Beadell Investment Counsel Inc. now owns 47,211 shares of the biopharmaceutical company’s stock valued at $1,252,000 after purchasing an additional 3,375 shares during the last quarter. ST Germain D J Co. Inc. grew its stake in Pfizer by 17.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 30,269 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 4,515 shares during the last quarter. Finally, ORG Partners LLC grew its stake in Pfizer by 6.2% during the 4th quarter. ORG Partners LLC now owns 50,879 shares of the biopharmaceutical company’s stock valued at $1,351,000 after purchasing an additional 2,967 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Guggenheim dropped their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Sanford C. Bernstein assumed coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Price Performance

Shares of PFE stock traded down $0.04 during trading hours on Friday, reaching $26.82. The company had a trading volume of 20,441,562 shares, compared to its average volume of 33,425,488. The company has a market capitalization of $151.99 billion, a price-to-earnings ratio of 36.24, a PEG ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a fifty day moving average of $26.21 and a 200-day moving average of $28.05.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the business posted ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.41%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.